LifeMD (NASDAQ:LFMD) Given Buy Rating at HC Wainwright

LifeMD (NASDAQ:LFMD - Get Free Report)'s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report released on Thursday, September 17th, Marketbeat.com reports. They currently have a $9.00 target price on the stock. HC Wainwright's price objective would indicate a potential upside of 209.28% from the stock's current price.

A number of other research analysts have also recently issued reports on the company. Mizuho set a $7.00 target price on LifeMD in a research report on Thursday, August 6th. Zacks Research raised shares of LifeMD from a "strong sell" rating to a "hold" rating in a report on Monday, August 17th. Wall Street Zen cut shares of LifeMD from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. UBS Group reiterated a "buy" rating on shares of LifeMD in a research note on Wednesday, May 27th. Finally, BTIG Research cut their price objective on LifeMD from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, LifeMD currently has a consensus rating of "Moderate Buy" and an average price target of $7.57.

LifeMD Stock Performance

Shares of NASDAQ LFMD traded down $0.14 during trading hours on Thursday, hitting $2.91. 855,407 shares of the stock were exchanged, compared to its average volume of 1,045,043. The company's fifty day simple moving average is $3.43 and its two-hundred day simple moving average is $4.01. The company has a market cap of $140.26 million, a PE ratio of -58.19 and a beta of 2.04. LifeMD has a 1-year low of $2.56 and a 1-year high of $7.32.

LifeMD (NASDAQ:LFMD - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%.The business had revenue of $47.28 million for the quarter, compared to the consensus estimate of $49.16 million. As a group, sell-side analysts expect that LifeMD will post -0.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. State Street Corp grew its position in shares of LifeMD by 22.6% in the 2nd quarter. State Street Corp now owns 1,318,784 shares of the company's stock valued at $5,447,000 after buying an additional 243,376 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of LifeMD in the second quarter worth approximately $113,000. Integrated Wealth Concepts LLC acquired a new stake in LifeMD during the 2nd quarter valued at approximately $25,000. Penn Capital Management Company LLC acquired a new position in shares of LifeMD in the 2nd quarter worth approximately $926,000. Finally, Corient Private Wealth LP bought a new stake in LifeMD during the second quarter valued at $63,000. 35.52% of the stock is owned by institutional investors.

About LifeMD

LifeMD, Inc NASDAQ: LFMD is a U.S.-based telehealth company that provides virtual healthcare services through its digital platform. The company connects patients with licensed healthcare professionals through online consultations, enabling access to medical care, prescriptions, ongoing treatment and care-management services without requiring an in-person visit.

LifeMD offers services across several areas, including virtual primary care, men's and women's health, dermatology, mental health and weight management.